Simvastatin
- Generic Name
- Simvastatin
- Brand Names
- Cholib, FloLipid, Simcor, Vytorin, Zocor
- Drug Type
- Small Molecule
- Chemical Formula
- C25H38O5
- CAS Number
- 79902-63-9
- Unique Ingredient Identifier
- AGG2FN16EV
- Background
Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of Aspergillus terreus. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liv...
- Indication
Simvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL‑C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C).
...
- Associated Conditions
- Cardiovascular Events, Diabetes Mellitus, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Mixed Hyperlipidemia, History of coronary heart disease cardiovascular event, History of stroke or other cerebrovascular disease cardiovascular event
- Associated Therapies
- -
Efficacy of Lapaquistat Acetate Alone or Combined With Simvastatin in Subjects With Hypercholesterolemia
- Conditions
- Interventions
- First Posted Date
- 2006-02-03
- Last Posted Date
- 2012-05-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1362
- Registration Number
- NCT00286481
Effects of Statins on Pro- and Antioxidant Status : Link With Statin-Associated Myopathy.
- Conditions
- First Posted Date
- 2006-02-01
- Last Posted Date
- 2007-08-09
- Lead Sponsor
- University Hospital, Montpellier
- Target Recruit Count
- 24
- Registration Number
- NCT00285181
- Locations
- 🇫🇷
Centre d'Investigation Clinique, Montpellier, France
The Effect of High Dose Simvastatine on Multiple Myeloma
- Conditions
- First Posted Date
- 2006-01-24
- Last Posted Date
- 2011-11-01
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT00281476
A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).
- Conditions
- First Posted Date
- 2005-12-20
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 640
- Registration Number
- NCT00267280
- Locations
- 🇺🇸
Pfizer Investigational Site, Tacoma, Washington, United States
A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.
- Conditions
- First Posted Date
- 2005-12-20
- Last Posted Date
- 2007-11-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 640
- Registration Number
- NCT00267254
- Locations
- 🇺🇸
Pfizer Investigational Site, Milwaukee, Wisconsin, United States
Simvastatin Treatment of Patients With Acute Optic Neuritis
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2011-01-10
- Lead Sponsor
- Glostrup University Hospital, Copenhagen
- Target Recruit Count
- 64
- Registration Number
- NCT00261326
- Locations
- 🇩🇰
The clinic of the research for optic neuritis and MS, The Dpt. of Neurology at Glostrup Hospital, Glostrup, Denmark
PROMISS: Simvastatin Prevents the Contrast Induced Acute Renal Failure in Patients With Renal Insufficiency Undergoing Coronary Angiography
- Conditions
- First Posted Date
- 2005-11-29
- Last Posted Date
- 2007-07-12
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 320
- Registration Number
- NCT00259441
- Locations
- 🇰🇷
Seoul National University Hospital , Cardiovascular Center, Seoul, Korea, Republic of
Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia.
- Conditions
- Interventions
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2012-05-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 411
- Registration Number
- NCT00256178
A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia
- Conditions
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2014-08-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 871
- Registration Number
- NCT00254475
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
Evaluation of Efficacy and Safety of Combined Omacor (Omega-3-acid Ethyl Esters) and Simvastatin Therapy in Hypertriglyceridemic Subjects
- Conditions
- Interventions
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 256
- Registration Number
- NCT00246701
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.